Compare eBay Inc (EBAY) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
eBay Inc vs Gilead Sciences, Inc. — how do they compare? eBay Inc trades at $111.7 (market cap $47.88B), while Gilead Sciences, Inc. trades at $147.1 (market cap $182.09B). The key difference: Gilead Sciences, Inc. is far larger — about 3.8× eBay Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold eBay Inc for 134 Days and Gilead Sciences, Inc. for 111 Days on average.
| EBAY | GILD | |
|---|---|---|
Market Cap | $47.88B | $182.09B |
Volume | 2,781,198 | 4,960,247 |
Sector | Consumer Cyclical | Health |
52-Week High | $118.96 | $155.80 |
52-Week Low | $79.41 | $116.74 |
Typical Hold Time | 134 Days | 111 Days |
Enterprise Value | $51.71B | $205.15B |
Dividend Yield | 1.15% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EBAY trades at $111.98, up 4.6% with bullish technical signals and strong earnings momentum after beating Q2 2026 estimates. The company maintains robust profitability with 72% gross margins and 47% ROE, while analyst consensus targets $117.68. Recent news highlights strategic focus on collectibles and live commerce growth, though GameStop's acquisition interest and executive selling warrant monitoring.
EBAY presents a balanced investment case with solid fundamentals and positive technicals, but faces competitive pressures from Amazon's multi-platform tools and potential acquisition uncertainty. The stock offers moderate upside to consensus targets with execution-dependent growth in key verticals.
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About eBay Inc
eBay Inc. is a global commerce company. The Company's platforms are designed to enable sellers worldwide to organize and offer their inventory for sale and buyers to find and buy it. eBay's items can be new or used, plain or luxurious, commonplace or rare, trendy or one-of-a-kind.
Read more on EBAY →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
